Walleye Capital
AUPH icon

Walleye Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Walleye Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
7,300
+3,100
+74% +$49.5K ﹤0.01% 3769
2026
Q1 		$62.2K Sell
4,200
-21,200
-83% -$310K ﹤0.01% 3836
2025
Q4 		$405K Buy
25,400
+24,300
+2,209% +$344K ﹤0.01% 3088
2025
Q3 		$12.2K Sell
1,100
-6,000
-85% -$65.5K ﹤0.01% 4266
2025
Q2 		$60.1K Sell
7,100
-7,700
-52% -$61.7K ﹤0.01% 3976
2025
Q1 		$119K Sell
14,800
-29,500
-67% -$239K ﹤0.01% 3544
2024
Q4 		$398K Sell
44,300
-6,400
-13% -$52.2K ﹤0.01% 3178
2024
Q3 		$372K Buy
+50,700
New +$314K ﹤0.01% 3567
2024
Q2 		– Sell
-17,700
Closed -$88.7K – 5571
2024
Q1 		$88.7K Buy
+17,700
New +$120K ﹤0.01% 4448
2023
Q1 		– Sell
-1,000
Closed -$4.32K – 3926
2022
Q4 		$4.32K Hold
1,000
– – ﹤0.01% 2877
2022
Q3 		$8K Buy
+1,000
New +$8.66K ﹤0.01% 2855

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's AUPH Position: Q2 2026 in Review

Walleye Capital reduced its Aurinia Pharmaceuticals (AUPH) stake by 80% in Q2 2026, selling an estimated $4.09M and leaving 65,696 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Walleye Capital first reported a position in AUPH in Q4 2019 and has held it in 11 quarters since. The position peaked at $4.77M in Q1 2026. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Walleye Capital held 65,696 shares of Aurinia Pharmaceuticals worth $1.11M as of Q2 2026.
  • Walleye Capital sold 255,871 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $4.09M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2020 holding.
  • Walleye Capital first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
  • Walleye Capital's Aurinia Pharmaceuticals position peaked at $4.77M in Q1 2026.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.